Tin tức & Cập nhật

In the treatment of patients with muscle-invasive bladder cancer (MIBC), a perioperative regimen of the antibody–drug conjugate sacituzumab govitecan plus pembrolizumab yields a promising clinical complete response rate without eliciting grade ≥4 adverse events (AEs), allowing bladder preservation without further therapy in some patients, according to the phase II SURE-02 trial.

The addition of hormone therapy, either short- or long-term, to postoperative radiotherapy (PORT) offers no survival advantage over PORT alone in prostate cancer, especially for men with very low pre-PORT prostate specific antigen (PSA) levels, according to the POSEIDON study.

Adding enzalutamide to radium-223 significantly improves overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with enzalutamide alone, according to the phase III EORTC 1333/PEACE-3 trial presented at ASCO GU 2026.

Treatment with sacituzumab tirumotecan (sac-TMT) shows a promising antitumour activity and an acceptable safety profile in patients with heavily pretreated advanced or metastatic urothelial carcinoma (UC), according to a phase II study.

New drug applications approved by US FDA as of 1-15 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A recent study has found that employment in managerial and professional positions across early and mid-adulthood may result in a reduced risk for lower urinary tract symptoms (LUTS) at midlife, while that in service positions tends to increase such risk.